Dapagliflozin/saxagliptin
![]() | This article relies too much on references to primary sources. (July 2020) |
Combination of | |
---|---|
Dapagliflozin | SGLT-2 inhibitor |
Saxagliptin | Dipeptidyl peptidase-4 inhibitor |
Clinical data | |
Trade names | Qtern |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
KEGG |
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]
Medical uses[]
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
- to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.[3]
- when already being treated with saxagliptin and dapagliflozin.[3]
References[]
- ^ a b "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
- ^ a b c d e "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
- ^ a b c d e f g h "Qtern EPAR". European Medicines Agency (EMA). Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.
External links[]
- "Dapagliflozin propanediol". Drug Information Portal. U.S. National Library of Medicine.
- "Saxagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Dapagliflozin". MedlinePlus.
- "Saxagliptin". MedlinePlus.
- Adamantanes
- Anti-diabetic drugs
- AstraZeneca brands
- Carboxamides
- Chloroarenes
- Combination drugs
- Dipeptidyl peptidase-4 inhibitors
- Glucosides
- Nitriles
- Nitrogen heterocycles
- Phenol ethers
- SGLT2 inhibitors
- Tertiary alcohols
- Gastrointestinal system drug stubs